Mesenchymal markers such as vimentin/fibronectin/N-cadherin have been reported to be over-expressed either at the genetic level or at the protein level on treating ovarian cancer cells or cell lines in various studies. This evidence concerns the gene CDH2 and ovarian carcinoma.